文献速递乳腺癌支持与姑息治疗

实体瘤放射敏感性与免疫激活相关

Tumour radiosensitivity is associated with immune activation in solid tumours.
PubMed 文献 · Eur J Cancer · 2017-08-29

研究基于10240例实体原发肿瘤的基因表达数据,发现放射敏感性指数(RSI)低的肿瘤其12趋化因子免疫激活签名(12-CK)中位值显著更高。在282例早期乳腺癌探索性分析中,RSI与12-CK对无远处转移生存的贡献相当。

要点

  • RSI-low肿瘤(n=4291,41.9%)的12-CK中位值0.54,高于RSI-high肿瘤的-0.17(p<0.001)。
  • 早期乳腺癌多变量模型显示RSI的HR为0.63,12-CK的HR为0.66,对DMFS贡献相当。
  • RSI与12-CK联合模型对DMFS有显著预测价值(p=0.02)。

核心结论

  • 以两种基因表达签名衡量,实体瘤的放射敏感性与免疫激活相关。

研究设计与样本

  • 利用机构去标识数据库,纳入10240例经基因组分析的实体原发肿瘤进行基因表达分析。
  • 采用RSI(10基因签名,衡量放射敏感性,评分越低放射敏感性越高)和12-CK(12基因签名,衡量免疫激活,评分越高免疫激活越高)。
  • 另在282例仅接受手术和术后放疗、未接受全身治疗的早期乳腺癌独立队列中探索性分析预后意义。

主要发现

  • 以RSI≤0.3745为切点,RSI-low肿瘤(n=4291,41.9%)的12-CK中位值为0.54(-0.136,1.095),RSI-high肿瘤为-0.17(-0.82,0.42),差异有统计学意义(p<0.001)。
  • 早期乳腺癌探索性分析中,包含年龄、RSI和12-CK的多变量模型对DMFS有显著预测价值(p=0.02)。
  • RSI的HR为0.63(95%CI 0.36,1.09),12-CK的HR为0.66(95%CI 0.41,1.04),两者贡献相当。

关键数值与推荐

  • RSI切点为≤0.3745,用于定义RSI-low肿瘤。
  • RSI-low肿瘤的12-CK中位值为0.54(-0.136,1.095),RSI-high肿瘤为-0.17(-0.82,0.42)。
  • 多变量模型中RSI的HR为0.63(95%CI 0.36,1.09),12-CK的HR为0.66(95%CI 0.41,1.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our goal was to determine whether tumour radiosensitivity is associated with activation of the immune system across all tumour types as measured by two gene expression signatures (GESs). METHODS: We identified 10,240 genomically profiled distinct solid primary tumours with gene expression analysis available from an institutional de-identified database. Two separate GESs were included in the analysis, the radiosensitivity index (RSI) GES (a 10-gene GES as a measure of radiosensitivity) and the 12-chemokine (12-CK) signature (a 12-gene GES as a measure of immune activation). We tested whether the RSI and 12-CK were associated with each other across all tumour samples and, in an exploratory analysis, their prognostic significance in predicting distant metastasis-free survival (DMFS) among a well-characterised, independent cohort of 282 early-stage breast cancer cases treated with surgery and post-operative radiation alone without systemic therapy. The lower the RSI score, the higher the tumour radiosensitivity; whereas, the higher the 12-CK score the higher the immune activation. RESULTS: Using an RSI cut-point of ≤0.3745, RSI-low tumours (n = 4,291, 41.9%) had a significantly higher median 12-CK GES value (0.54 [-0.136, 1.095]) compared with RSI-high tumours (-0.17 [-0.82, 0.42]; p < 0.001) across all tumour samples, indicating that radiosensitivity is associated with immune activation. In an exploratory analysis of early-stage breast cancer cases, a multivariable model with patient age, RSI and 12-CK provided a strong composite model for DMFS (p = 0.02), with RSI (hazard ratio [HR] 0.63 [95% confidence interval 0.36, 1.09]) and 12-CK (HR 0.66 [0.41, 1.04]) each providing comparable contributions. CONCLUSIONS: Tumour radiosensitivity is associated with immune activation as measured by the two GESs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Strom T, Harrison LB, Giuliano AR, et al. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017. PMID: 28863385. doi:10.1016/j.ejca.2017.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。